Stoke Therapeutics Inc STOK:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$13.51Cboe Real-Time Last Sale as of 11:30AM ET 6/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.09(0.66%)
Bid (Size)$13.45 (45)
Ask (Size)$13.53 (6)
Day Low / High$13.09 - 14.11
Volume34.6 K
Sell
Buy
Chart Style Historical Chart Icon Download historical data
 

View Biotechnology IndustryPeer Comparison as of 06/27/2022

Timeframe
 

Stoke Therapeutics Inc ( NASDAQ )

Price: $13.51
Change: -0.09 (0.66%)
Volume: 34.6 K
11:30AM ET 6/27/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Ocugen Inc ( NASDAQ )

Price: $2.49
Change: -0.02 (0.80%)
Volume: 1.7 M
11:30AM ET 6/27/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Geron Corp ( NASDAQ )

Price: $1.42
Change: +0.05 (3.65%)
Volume: 174.4 K
11:29AM ET 6/27/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Agenus Inc ( NASDAQ )

Price: $1.92
Change: +0.02 (1.05%)
Volume: 651.7 K
11:30AM ET 6/27/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

MaxCyte Inc ( NASDAQ )

Price: $4.89
Change: -0.14 (2.78%)
Volume: 149.5 K
11:27AM ET 6/27/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain

Read more news Recent News

Cantor Fitzgerald Adjusts Price Target for Stoke Therapeutics to $38 From $68, Retains Overweight Rating
11:26AM ET 5/26/2022 MT Newswires

Stoke Therapeutics (STOK) has an average buy rating among analysts, with a price target range of $38 to $70. (MT Newswires covers equity, commodity and...

Stoke Therapeutics Files $400 Million Mixed Shelf
3:24AM ET 5/23/2022 MT Newswires

Stoke Therapeutics (STOK) on Friday filed a shelf registration statement for the potential sale of up to $400 million of its securities from time to time. ...

--Credit Suisse Lowers Stoke Therapeutics' Price Target to $54 from $58, Keeps Outperform Rating
10:41AM ET 5/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Adjusts Price Target for Stoke Therapeutics to $33 From $32, Maintains Outperform Rating
2:51PM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Stoke Therapeutics (STOK) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
2:22PM ET 1/24/2022 Seeking Alpha

Stoke Therapeutics (STOK) Investor Presentation -Slideshow
2:11AM ET 12/01/2021 Seeking Alpha

Company Profile

Business DescriptionStoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA. View company web site for more details
Address45 Wiggins Avenue
Bedford, Massachusetts 01730
Phone+1.781.430.8200
Number of EmployeesN/A
Chief Executive Officer & DirectorEdward M. Kaye
Chief Operating & Business OfficerHuw M. Nash
Chief Financial OfficerStephen J. Tulipano
Chief Medical OfficerBarry S. Ticho

Company Highlights

Price Open$13.55
Previous Close$13.60
52 Week Range$9.55 - 35.73
Market Capitalization$528.8 M
Shares Outstanding39.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.54
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-3,122.03%
Return on Equity-39.42%

Analyst Ratings as of 03/17/2022

Buy
11
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset